**ReMuS – CZECH NATIONAL REGISTRY OF MULTIPLE SCLEROSIS PATIENTS – 2 YEARS EXPERIENCE**

**BACKGROUND**

Multiple sclerosis is a lifelong disease with a very heterogenous clinical course. Randomised controlled clinical trials bring reliable but only short term data. Long term data from real life conditions are needed.

**OBJECTIVES**

To report a structure, evolution, and first results from the Czech national registry ReMuS.

**METHODS**

The ReMuS is operated and completely funded by the Endowment Fund IMPULS (www.impuls.cz) in collaboration with the Czech neuroimmunological society - SCLEROSIS PATIENTS – 2 YEARS EXPERIENCE (www.sclerosis.cz) in Prague and Motol University Hospital. The ReMuS is funded by Endowment Fund IMPULS. This database is supported by Prague Center for Perinatal Research. The registry is administered by the Institute of Clinical and Experimental Medicine (www.icr.cz) in Prague, and also serves as an important scientific platform for future endeavors. The registry provides further data about distribution of patients in particular regions, health insurance assignment, and important data about employment and disability pension (67.8% of patients are employed and working full or part time). The registry will soon provide comprehensive data of more than 7000 patients. The aim is to enrol a majority of MS patients (approx. 13000) in the Czech Republic within the next 2 years. The registry will soon provide not only crosssectional, but also important longitudinal data. This will help to better organise care for MS patients in the Czech Republic and also serve as an important scientific platform for future endeavors.

**RESULTS**

13 out of 15 Czech MS centres have already joined the registry. The number of patient records has increased gradually from 1501 to 7099 in the last export in June 2015. Table 1 and Fig 2.

**CONCLUSIONS**

ReMuS, the Czech national registry, has already collected comprehensive data of more than 7000 patients. The aim is to enrol a majority of MS patients (approx. 13000) in the Czech Republic within the next 2 years. The registry will soon provide not only crosssectional, but also important longitudinal data. This will help to better organise care for MS patients in the Czech Republic and also serve as an important scientific platform for future endeavors.

**Figure 1** ReMuS – project organization

**Figure 2** Total number of analysed patients by centres

**Figure 3** Patient distribution by EDSS degree

**Figure 4** Medicinal preparations used – Disease Modifying Drugs and Intravenous immunoglobulins

**Figure 5** Patient distribution by employment type